Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
On 6ix: 6ix.com/news/ocular-therapeutixtm-announces-positive-phase-2-paxtravatm-glaucoma-data-at-the
Watch Ocular Therapeutix's latest callOcular Therapeutix (NASDAQ:OCUL) Q1 2026 Earnings Call · Replay · May 5Read the transcript of Ocular Therapeutix (NASDAQ:OCUL) Q1 2026 Earnings CallOcular Therapeutix's next earnings callOcular Therapeutix (NASDAQ:OCUL) Q3 2026 Earnings Call · Nov 9, 2026 at 8:00 AM ESTRegister
Ocular Therapeutix, Inc. on 6ix
Story so far
- Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
- Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
- Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
Earlier from Ocular Therapeutix
- Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
- Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
- Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
- Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
- Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
Later from Ocular Therapeutix
- Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
- Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
- Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
- Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
- Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
Follow Ocular Therapeutix into a list and get an email when it puts out news.
Follow Ocular Therapeutix